{
  "cutoff": "2026-10-13",
  "note": "Selected publication milestones, not an exhaustive history or discovery priority claim.",
  "milestones": [
    {
      "pmid": "18818038",
      "year": "2009",
      "title": "Incidental findings in healthy control research subjects using whole-body MRI.",
      "doi": "10.1016/j.ejrad.2008.08.006",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18818038/",
      "interpretation": "Healthy-volunteer whole-body MRI shows frequent incidental findings, motivating disclosure and follow-up questions."
    },
    {
      "pmid": "21714641",
      "year": "2011",
      "title": "Reduced lung-cancer mortality with low-dose computed tomographic screening.",
      "doi": "10.1056/NEJMoa1102873",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21714641/",
      "interpretation": "NLST directly demonstrates lung-mortality benefit from an allocated screening programme in high-risk smokers; other-assay mortality proof is possible but not transferable."
    },
    {
      "pmid": "22911290",
      "year": "2013",
      "title": "Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management.",
      "doi": "10.1007/s00330-012-2636-6",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22911290/",
      "interpretation": "SHIP quantifies general-population MRI incidental findings and management, with many abnormalities still uncertain."
    },
    {
      "pmid": "23239059",
      "year": "2013",
      "title": "Psychosocial consequences and severity of disclosed incidental findings from whole-body MRI in a general population study.",
      "doi": "10.1007/s00330-012-2723-8",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23239059/",
      "interpretation": "Incidental-finding recipients report distress despite high satisfaction, distinguishing experience from outcome benefit."
    },
    {
      "pmid": "27501770",
      "year": "2016",
      "title": "Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.",
      "doi": "10.1016/S1470-2045(16)30249-2",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27501770/",
      "interpretation": "Hereditary TP53 comprehensive surveillance is associated with survival in a self-selected high-risk cohort; this is a distinct package and population."
    },
    {
      "pmid": "29348365",
      "year": "2018",
      "title": "Detection and localization of surgically resectable cancers with a multi-analyte blood test.",
      "doi": "10.1126/science.aar3247",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29348365/",
      "interpretation": "CancerSEEK provides original multi-analyte case-control discrimination, requiring subsequent prospective clinical validation."
    },
    {
      "pmid": "29565420",
      "year": "2018",
      "title": "False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.",
      "doi": "10.1038/gim.2018.38",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29565420/",
      "interpretation": "DTC raw-data clinical confirmation reveals selected false variants and interpretation errors, with a referral-based denominator."
    },
    {
      "pmid": "31260833",
      "year": "2019",
      "title": "Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial.",
      "doi": "10.1016/j.jtho.2019.05.044",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31260833/",
      "interpretation": "Extended NLST follow-up illustrates horizon-dependent effects and why repeated reports must retain one parent trial."
    },
    {
      "pmid": "31995683",
      "year": "2020",
      "title": "Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.",
      "doi": "10.1056/NEJMoa1911793",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31995683/",
      "interpretation": "NELSON provides another true high-risk lung-mortality screening result with long outcome follow-up."
    },
    {
      "pmid": "32345712",
      "year": "2020",
      "title": "Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.",
      "doi": "10.1126/science.abb9601",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32345712/",
      "interpretation": "DETECT-A prospectively combines blood testing with PETCT and finds treatable cancers, without a randomized mortality control."
    },
    {
      "pmid": "32694610",
      "year": "2020",
      "title": "Non-invasive early detection of cancer four years before conventional diagnosis using a blood test.",
      "doi": "10.1038/s41467-020-17316-z",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32694610/",
      "interpretation": "Stored PanSeer samples show potential years-earlier signals; retrospective detection does not itself demonstrate intervention utility."
    },
    {
      "pmid": "33991479",
      "year": "2021",
      "title": "Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.",
      "doi": "10.1016/S0140-6736(21)00731-5",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33991479/",
      "interpretation": "UKCTOCS directly separates favorable stage movement from unchanged ovarian/tubal mortality after16.3years."
    },
    {
      "pmid": "34176681",
      "year": "2021",
      "title": "Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.",
      "doi": "10.1016/j.annonc.2021.05.806",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34176681/",
      "interpretation": "CCGA's independent validation characterizes stage-sensitive diagnostic performance in known cases and controls."
    },
    {
      "pmid": "36214590",
      "year": "2022",
      "title": "Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death.",
      "doi": "10.1056/NEJMoa2208375",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36214590/",
      "interpretation": "NordICC reduces colorectal incidence at10years while mortality remains nonsignificant, emphasizing outcome hierarchy and screening uptake."
    },
    {
      "pmid": "37805216",
      "year": "2023",
      "title": "Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.",
      "doi": "10.1016/S0140-6736(23)01700-2",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37805216/",
      "interpretation": "PATHFINDER measures real prospective detection and diagnostic workups, with false-positive delays and no mortality comparison."
    },
    {
      "pmid": "38581198",
      "year": "2024",
      "title": "Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.",
      "doi": "10.1001/jama.2024.4011",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38581198/",
      "interpretation": "CAP's15-year secondary prostate-death effect demonstrates the importance of long follow-up, absolute effect and disease-specific context."
    },
    {
      "pmid": "41173830",
      "year": "2025",
      "title": "Real-world data and clinical experience from over 100,000 multi-cancer early detection tests.",
      "doi": "10.1038/s41467-025-64094-7",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41173830/",
      "interpretation": "Large real-world Galleri data expose voluntary outcome reporting and symptom-specific denominators that constrain interpretation."
    },
    {
      "pmid": "42773209",
      "year": "2026",
      "title": "Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial.",
      "doi": "10.1038/s41591-026-04652-8",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42773209/",
      "interpretation": "NHS intervention-arm performance provides population-screening metrics, not a second randomized mortality result."
    },
    {
      "pmid": "42776074",
      "year": "2026",
      "title": "Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis.",
      "doi": "10.1056/NEJMoa2505723",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42776074/",
      "interpretation": "The current NHS randomized primary combined-stage result is null, with a favorable secondary stageIV signal and mortality follow-up still needed."
    }
  ],
  "gaps": [
    "Exact Galleri randomized cancer-mortality follow-up rather than surrogate stage outcomes",
    "Site-specific and assay-version-specific stage-to-mortality validation",
    "Systematic interval-cancer and false-negative follow-up, especially in real-world use",
    "Overdiagnosis versus beneficial interception, requiring long-term excess-incidence and outcome assessment",
    "Diagnostic capacity, patient-level harms and procedure/treatment burden under usual implementation",
    "Performance transportability across risk, ethnicity, prior cancer and care systems",
    "Independent general-population MRI and DTC benefit-harm trials rather than hereditary or diagnostic-referral extrapolation"
  ],
  "decisive_experiment": "Continue or run a randomized intention-to-screen comparison of specified Galleri plus usual care versus usual care in asymptomatic adults≥50, preserving established screening and treatment access. Prespecify cancer-specific mortality, all-cause mortality, site-specific deaths, diagnostic procedures, treatment morbidity, interval cancers and sustained incidence differences over an adequate horizon. Use blinded death adjudication and systematic outcome linkage in both arms. Stage shifts are candidate mediators, with predefined surrogate validation rather than conversion into modeled saved lives."
}